ABIOMED, Inc. (NASDAQ:ABMD) Given Consensus Recommendation of Hold by Analysts – Riverton Roll

Shares of ABIOMED, Inc. (NASDAQ:ABMD) have received an average rating of Hold from the eleven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $259.33.

Several research analysts have recently issued reports on ABMD shares. ValuEngine raised ABIOMED from a sell rating to a hold rating in a research report on Wednesday, September 4th. BidaskClub upgraded ABIOMED from a sell rating to a hold rating in a research report on Thursday, November 7th. Raymond James cut ABIOMED from an outperform rating to a market perform rating in a research note on Tuesday, October 29th. Morgan Stanley decreased their price objective on ABIOMED from $215.00 to $198.00 and set an equal weight rating for the company in a report on Tuesday. Finally, Leerink Swann increased their price objective on ABIOMED from $195.00 to $240.00 and gave the stock an outperform rating in a report on Friday, November 1st.

Institutional investors and hedge funds have recently made changes to their positions in the business. Nomura Holdings Inc. grew its stake in shares of ABIOMED by 95.5% in the 2nd quarter. Nomura Holdings Inc. now owns 7,709 shares of the medical equipment providers stock worth $2,043,000 after buying an additional 3,765 shares during the last quarter. Nuveen Asset Management LLC boosted its holdings in ABIOMED by 17,845.5% in the second quarter. Nuveen Asset Management LLC now owns 197,759 shares of the medical equipment providers stock worth $51,514,000 after acquiring an additional 196,657 shares in the last quarter. CIBC Asset Management Inc grew its stake in shares of ABIOMED by 2.1% in the second quarter. CIBC Asset Management Inc now owns 4,093 shares of the medical equipment providers stock worth $1,066,000 after acquiring an additional 85 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of ABIOMED by 13.3% in the third quarter. SG Americas Securities LLC now owns 8,144 shares of the medical equipment providers stock worth $1,449,000 after acquiring an additional 958 shares during the last quarter. Finally, Commerce Bank purchased a new stake in shares of ABIOMED in the second quarter worth $330,000. Institutional investors and hedge funds own 90.68% of the companys stock.

Shares of NASDAQ ABMD traded down $6.54 during midday trading on Monday, hitting $162.89. 2,022,308 shares of the company traded hands, compared to its average volume of 622,237. ABIOMED has a 12-month low of $155.02 and a 12-month high of $364.31. The stock has a 50-day moving average price of $196.74 and a 200 day moving average price of $211.02. The firm has a market cap of $7.65 billion, a P/E ratio of 45.25, a P/E/G ratio of 1.51 and a beta of 0.32.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, October 31st. The medical equipment provider reported $1.03 EPS for the quarter, topping the Thomson Reuters consensus estimate of $0.93 by $0.10. The business had revenue of $204.97 million during the quarter, compared to analyst estimates of $206.45 million. ABIOMED had a net margin of 26.92% and a return on equity of 19.89%. ABIOMEDs quarterly revenue was up 12.8% compared to the same quarter last year. During the same period last year, the business posted $1.09 earnings per share. Sell-side analysts predict that ABIOMED will post 4.31 earnings per share for the current year.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Featured Story: How to interpret the current ratio

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

See original here:
ABIOMED, Inc. (NASDAQ:ABMD) Given Consensus Recommendation of Hold by Analysts - Riverton Roll